Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
J Cell Mol Med. 2020 Apr;24(8):4839-4849. doi: 10.1111/jcmm.15163. Epub 2020 Mar 16.
Lung cancer leads to the highest mortality among all cancer types in the world, and non-small-cell lung cancer (NSCLC) occupies over 80% of the lung cancer cases. Numerous studies have demonstrated that long non-coding RNA (lncRNA) is involved in various human diseases including cancer. LncRNA FTX was firstly identified in Xist gene locus and was dysregulated in many human cancers. However, the function of FTX in NSCLC is still unclear. Here, we report that long non-coding RNA FTX expression level is down-regulated in NSCLC clinical tissue samples and cell lines. Ectopic expression of FTX inhibits proliferation and metastasis of lung cancer cells in vitro and in vivo. Furthermore, we find that FTX overexpression activates the expression of transcription factor FOXA2, an important regulator in lung cancer progression, and we reveal a novel FTX/miR-200a-3p/FOXA2 competing endogenous RNA regulatory axis in lung cancer cells. Our results provide new insights and directions for exploring the function of FTX in lung cancer progression.
肺癌是全球所有癌症类型中导致死亡率最高的一种,非小细胞肺癌(NSCLC)占肺癌病例的 80%以上。大量研究表明,长链非编码 RNA(lncRNA)参与包括癌症在内的多种人类疾病。lncRNA FTX 最初在 Xist 基因座中被鉴定出来,并在许多人类癌症中失调。然而,FTX 在 NSCLC 中的功能尚不清楚。在这里,我们报告说,长链非编码 RNA FTX 的表达水平在 NSCLC 临床组织样本和细胞系中下调。FTX 的异位表达抑制肺癌细胞在体外和体内的增殖和转移。此外,我们发现 FTX 的过表达激活了转录因子 FOXA2 的表达,FOXA2 是肺癌进展中的一个重要调节因子,我们在肺癌细胞中揭示了一个新的 FTX/miR-200a-3p/FOXA2 竞争性内源性 RNA 调节轴。我们的研究结果为探索 FTX 在肺癌进展中的功能提供了新的见解和方向。